C S E : C A N A O T C : C N N X F
C S E : C A N A O T C : C N N X F CANNAMERICA BRANDS CORPORATE - - PowerPoint PPT Presentation
C S E : C A N A O T C : C N N X F CANNAMERICA BRANDS CORPORATE - - PowerPoint PPT Presentation
C S E : C A N A O T C : C N N X F CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019 DISCLAIMER NOT FOR DISTRIBUTION; NO OFFERING licensing agreements and planned partnerships and the successful commencement of above neither the Company nor
CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019
2
DISCLAIMER
NOT FOR DISTRIBUTION; NO OFFERING The information contained herein has been prepared to assist interested parties in making their own evaluation of the Company and its business and does not purport to contain all the information that prospective investors may require. Prospective investors should conduct their own investigation and analysis of the Company and its business and the information contained in this presentation as well as any additional information provided by the Company. The information contained in this presentation is not to be used for any other purpose. The information in this presentation must be kept confidential at all times. By accepting this presentation, the recipient agrees that it will not copy, duplicate or distribute this presentation, in whole or in part, at any time without the Company’s prior written consent. By your acceptance hereof, you covenant that neither you nor your agents, representatives, directors or employees will copy, reproduce or distribute this presentation or the information herein to others, in whole or in part, at any time, without the prior written consent of the Company, and that you will keep confidential this presentation, the information herein and any information otherwise obtained from the Company. No securities commission or similar authority in Canada or any other jurisdiction has in any way passed upon the adequacy or accuracy of the information contained in this Presentation. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Presentation contains forward-looking statements and forward-looking information within the meaning of applicable Canadian and United States securities
- legislation. Often, but not always, forward-looking statements can be identified by the
use of words or phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and unknown words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”,
- r variations of such words and risks, uncertainties and other factors which may cause
the actual results, performance or achievements of CannAmerica to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and information. Examples of such statements include statements about expected timelines for product acquisition and launches, completing financings, finalizing collaborations and contractual arrangements, market growth and size, CannAmerica’s strategies and objectives, future revenues, targeted EBITDA and profits, expected timing and receipt of necessary government licensing, forecast number of product lines and sales, the expectation of additional licensing agreements and planned partnerships and commencement of operations. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this
- Presentation. Such forward-looking statements are based on a number of assumptions
which may prove to be incorrect, including, but not limited to: the expected timelines for product acquisition and launches will be correct, the successful completion of financings, the successful finalization of collaborations and contractual arrangements, the market’s growth and size will be as anticipated, CannAmerica’s strategies will be successfully implemented to achieve its objectives, future revenues will be as anticipated, targeted EBITDA and profits will be as anticipated, expected timing and receipt of necessary government licensing will be as expected, forecast number of product lines and sales will be accurate, CannAmerica will enter into additional licensing agreements and planned partnerships and the successful commencement of
- perations. These forward-looking statements are subject to known and unknown
risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of CannAmerica to be materially different from those expressed or implied by such forward-looking statements or forward-looking
- information. Important factors that may cause actual results to vary, include, without
limitation, the risk that the expected timelines for product acquisition and launches will be incorrect, CannAmerica will not be able to close any additional financings, CannAmerica will be unable to successfully finalize collaborations and contractual arrangements, the market’s growth and size will be slower and smaller than anticipated, CannAmerica’s strategies will not be successfully implemented and CannAmerica will be unable to achieve its objectives, performance or achievements or such objectives, performance or achievements will be materially different from the estimated future results, expected timing and receipt of necessary government licensing will be delayed or denied, forecast number of product lines and sales will be inaccurate, CannAmerica will not be able to enter into additional licensing agreements and planned partnerships and the commencement of operations will be delayed or
- unsuccessful. These forward-looking statements should not be relied upon as
representing CannAmerica’s views as of any date subsequent to the date of this
- Presentation. Although CannAmerica has attempted to identify important factors that
could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward- looking statements and information contained in this Presentation are expressly qualified in their entirety by this cautionary statement. The forward-looking statements and information included in this Presentation are made as of the date of the sending
- f this Presentation and CannAmerica assumes no obligation to update such forward-
looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation. The focus of CannAmerica’s business is the cannabis industry. The production, distribution, sale and use of marijuana and its derivatives are still illegal in some of the jurisdictions in which CannAmerica intends to operate, including under federal law of the United States despite being legalized under some state laws. These laws and their enforcement are in flux and vary dramatically from jurisdiction to jurisdiction. The enforcement of these laws and its affect on CannAmerica and its business, employees, directors and shareholders are uncertain and accordingly involve considerable risk. This presentation contains information obtained by the Company from third parties, including but not limited to market data. The Company believes such information to be accurate but has not independently verified such information. To the extent such information obtained from third party sources, there is a risk that the assumptions made and conclusions drawn by the Company based on such representations are not
- accurate. This presentation may have been sent to you in an electronic form. You are
reminded that documents transmitted via this medium may be altered or changed during the process of electronic transmission. You are responsible for protecting against viruses and other destructive items. Your receipt of this electronic transmission is at your own risk and it is your responsibility to take precautions to ensure that it is free from viruses and other items of a destructive nature. As a consequence of the above neither the Company nor any director, officer or employee of the Company or any affiliate accepts any liability or responsibility whatsoever in respect of any difference between the document distributed to you in electronic format and the hard copy version that may be made available to you. CANNABIS-RELATED PRACTICES OR ACTIVITIES ARE ILLEGAL UNDER U.S. FEDERAL LAWS While the Company intends to operate its business in compliance with State Cannabis laws and regulations, the regulatory regime is complex and evolving. The Company may not be able to obtain the necessary licenses, permits or authority to operate its business as currently contemplated, which may have a material adverse effect on the Company’s anticipated business strategy and results of operations. The enforcement
- f U.S. federal laws or changes in the enforcement priorities and policies, the
Company’s inability to obtain licenses, permits or authority to operate its business as currently contemplated may adversely affect an investment in the Company’s
- securities. Prospective investors should refer to the more fulsome regulatory risk
disclosure included in the offering documents in respect of the proposed offering of securities, and in the Company’s (final) long form prospectus dated October 9, 2018. This presentation does not constitute an offer of securities, and no offer or sale of securities will be conducted in any jurisdiction where such offer or sale is prohibited. The securities being offered have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws and may not be offered or sold in the United States or to, or for the account or benefit of, “U.S. persons” as such term is defined in Regulation S under U.S. Securities Act (“U.S. Persons”) unless an exemption from registration is available. The securities being offered, if sold in the United States or to, or for the account of benefit of, U.S. Persons, will be “restricted securities” within the meaning of Rule 144 under the U.S. Securities Act. Such securities may be resold, pledged or otherwise transferred only pursuant to an effective registration statement under the U.S. Securities Act or pursuant to an applicable exemption from the registration requirements of the U.S. Securities Act. Prospective investors will be required to represent, among other things, that they meet the requirements of an available exemption from the registration requirements of the U.S. Securities Act and are familiar with and understand the terms of the offering and have all requisite authority to make such investment. IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE COMPANY AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. THE OFFERED SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR BY ANY STATE SECURITIES COMMISSION OR REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES OR ANY CANADIAN PROVINCIAL SECURITIES REGULATOR PASSED ON THE ACCURACY OR ADEQUACY OF THIS PRESENTATION. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019
CANNAMERICA OFFERS LICENSED AND REGULATED CANNABIS BUSINESSES AROUND THE WORLD THE OPPORTUNITY TO LICENSE THEIR WELL ESTABLISHED BRANDS.
Licensees receive the benefit of a recognized brand, including the flagship CannAmerica brand, as well as access to proprietary formulas, recipes, IP, packaging solutions, ingredients and trade secrets for creating high quality cannabis products.
The Company is also taking advantage of the demand in CBD with the more recent passing of the US Farm Bill.
3
CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019
$7
RAISED TO DATE TO ACQUIRE AND GROW THE CANNAMERICA AND AMERICANNA BRANDS. 4 We aim to maximize the value of our brands by promoting, marketing and licensing the brands through various distribution channels, including to dispensaries, wholesalers and distributors in the United States and internationally. Our core strategy is to enhance and monetize the global reach of our existing brands, and to pursue additional strategic acquisitions to grow the scope of and diversify our portfolio of brands. Management has deep knowledge in cannabis space. CEO Dan Anglin has been involved with drafting cannabis policy in Colorado for seven years, and remains a driving force in US dynamic and robust cannabis industry. Branding and licensing allows for high margins with low overhead compared to traditional cultivation and manufacturing licenses. CannAmerica has entered into strategic LOI’s with Serecia Labs in order to explore larger scale global CBD ventures.
EXECUTIVE SUMMARY
1 2 3 4 5
MILLION
CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019
Veteran
- wned and
- perated
“Clear Oil” distillate (vs. food grade oil) “Top Shelf” quality in product and process Focused on the message
- f freedom
and targets an audience who embraces that lifestyle
CannAmerica quickly developed as a highly-attractive brand in Colorado with over 14 million gummies sold because of the story it told:
Plan to have fully vertically integrated CBD business through relationship with Serecia Labs Entered CBD market in 2019 5
THE CANNAMERICA STORY
CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019
OUR LICENSING STRATEGY
01
6
CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019
Royalty payments based
- n fixed price per unit
Each licensee has specific geographical territories and distribution channels in which the licensed products may be sold Expand existing brands into multiple states as well as acquire new brands Raise capital and acquire established brands from manufacturers in exchange for long term licensing agreements
OUR LICENSING AND BRANDING AGREEMENTS GRANT THE LICENSEE:
7
LICENSING STRATEGY
Rights to the application, manufacture and/or production of certain proprietary blends, formulas and licensed products. We have created a proprietary blend of cannabis oil to be applied to the raw material (substrate) for the licensed products. Includes a precise ethanol formulation that has been designed to optimize the function of the equipment that is used to apply the blend to the substrate.
CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019
OUR LICENSEES
02
8
CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019 9
TR SCIENTIFIC
COLORADO
TR Scientific is located in Denver, Colorado Their team has years of experience operating closed loop extraction systems and producing world-class extracts using only the most advanced extraction equipment and techniques, ensuring that quality material always shines. Current selling through 350+ dispensaries in Colorado Operates a 25,000 sq ft Facility Plans to launch a new 25mg medical gummy as well as additional products in 2019
CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019 10
FLOWER ONE
NEVADA
Exclusive providers of gummies and other product lines Home to the largest cannabis cultivation greenhouse in Nevada at 450,000 square feet. Owner of the largest cannabis processing and custom packaging facility in Nevada, a 55,000 square foot operation. Capable of producing 140,000 lbs (or 62,500 kg) of dry flower per year and will house over 80,000 plants per crop cycle. Holds 9 licenses for medical and recreational cannabis cultivation and production in the state of Nevada. Boasts a diverse library of cannabis genetics which features
- ver 50 unique strains through its House Partner, NLVO.
C S E : F O N E | O T C Q B : F L O O F | w w w . f l o w e r o n e . c o m
CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019
0% 5% 10% 15% 20% 25% 30% 35% 40% 45% 50%
- 1,000
2,000 3,000 4,000 5,000 6,000 7,000 8,000 9,000 10,000 Dec-17 Jan-18 Feb-18 Mar-18 Apr-18 May-18 Jun-18
Thousands
MD Medicinal Cannabis Market Monthly Sales2
MD sales Sales % change from prior month
MARYLAND MARKET
The Maryland medical cannabis market has grown significantly on a monthly basis in the brief period since the first medical dispensary was approved in July, 20171.
1 https://medicalmarijuana.procon.org/view.resource.php?resourceID=000881#Maryland 2 https://mjbizdaily.com/chart-first-year-medical-marijuana-sales-maryland-could-hit-100-million
11
FGM PROCESSING
MARYLAND
FGM Processing is one of the first extraction licenses in Maryland Production commenced in August 2018 CannAmerica receives a Gross Revenue Royalty and revenue in USD per package for packaging/branding/intellectual property rights Operates a 7500 sq ft facility 1 of only 15 processor licenses in the state
- f Maryland
CannAmerica owns 10% of the license in Maryland
CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019 12
OKLAHOMA/ARKANSAS
THC, INC.
Exclusive license to manufacture and distribute CannAmerica branded products in Oklahoma and Arkansas Increasing awareness of brand and product lines in the Southern United States Multi-state right of first refusal
CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019 13
MASSACHUSETTS
CANNA PROVISIONS INC.
LOI with Canna Provisions Inc. (LOI expires August 15, 2019) Exclusive license to manufacture and distribute CannAmerica branded products in the Commonwealth of Massachusetts Increasing awareness of brand and product lines in the Eastern United States Multi-state right of first refusal
CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019
CBD GLOBAL MARKETS
03
14
CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019 15
MEXICO
SERICEA LABS
LOI to create a JV with CannAmerica / Sericea Labs / CBD Distribution Company LTD. LOI expires January 1, 2020 Build a large-scale hemp processing and manufacturing facility in Baja Mexico Exclusivity in Mexico ROFR for cannabis products if/when legalized in Mexico
CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019 16
CORPORATE STRUCTURE
*All currencies are in CAD unless stated otherwise
CannAmerica Brands Corp. CSE: CANA OTCQB: CNNXF Share Price (as of July 25, 2019) $0.15 CAD $0.12 USD Market Cap (as of July 25, 2019) $8M CAD $6M USD Avg Daily Share Volume (3-Mths) ~545k ~370k Management & Insider Ownership 10.5%
Share Metrics Number Price/ Share Dollars Shares Outstanding 52,453,684 $7,023,951 Stock Options 4,100,000 $0.30 $1,230,000 Warrants 3,000,000 $0.50 $1,500,000 Stock Options 3,700,000 $0.60 $2,220,000 Warrants 2,768,819 $0.80 $2,215,055 Total fully diluted shares
- utstanding
66,022,503 $12,191,006
Past Share Issuances Number Price/ Share Dollars Series A 300,000 $0.01 $3,000 Series B 7,060,000 $0.20 $1,412,000 Shares issued to acquire CannAmerica Brands Corp. 29,166,000 Series C 13,158,865 $0.30 $3,947,660 Series D 2,768,819 $0.60 $1,661,291 Total Raised to Date $7,023,951
16
CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019
MANAGEMENT TEAM
04
17
CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019
FRANK FALCONER
Founder, Chief Commercial Officer and Director
Frank’s involvement in the cannabis industry started in 2009 with the ownership and successful sale of marijuana edibles company, Wild Flour Baking Co. (“WFB”). Shortly after the sale of WFB, Frank shifted focus to distribution and development of new brands in the Colorado market. The impressive portfolio of infused-product brands he introduced into the market include: Edipure, EyeChronic, ExtractionTek, CRREO bags, Kush Bottles, ApotheCanna, PharmPods, Organa Labs Vape Pens (Open Vape), and Atmos Vape Pens. In addition to this list of brands he introduced into the market, he co-founded Denver Consulting Group (A Cannabis Consulting Firm, catering to clients nation-wide), Cannascore (a Compliance Audit Software Program, tracks compliance for cannabis
- perations, nation-wide), and now Americanna. Frank brings a unique, creative, intuitive
approach to cannabis brand development, and his successful portfolio has lead him to become one of the most trusted, sought-after players in the industry.
18
DAN ANGLIN
Founder, CEO and Director
A US Marine Veteran, Dan Anglin is Founder and CEO of AmeriCanna Brands, a Marijuana Infused Products manufacturer and cultivator
- f
both medical and recreational marijuana products in Colorado. Since 2011, Dan has been a high-profile leader in the marijuana industry, having owned and operated a successful recreational dispensary in Black Hawk Colorado, and co-owned one of the largest marijuana manufacturing companies in the world, EdiPure, operating in multiple states. Dan is also a national expert in marijuana public policy, serving on rule-making work groups for the Colorado Marijuana Enforcement Division on more than 10 occasions, as well as crafting legislation directly at the Colorado General Assembly for the good of Colorado and its regulated industry. Dan founded and is the Chairman of the Board of Directors of the Colorado Cannabis Chamber of Commerce, an industry-based trade
- rganization dedicated to advocacy and networking opportunities for the cannabis
industry, as well as promoting reasonable regulation on legal commercial cannabis
- businesses. Dan was selected as one of High Times 100 most influential people in
cannabis in 2018.
CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019
PAUL CIULLO CPA
CFO
- Mr. Ciullo has a diverse professional background and
specialized in financial reporting and project management during his time spent working in senior corporate finance and accounting positions for various Fortune 500
- companies. Mr. Ciullo’s most recent roles include serving as
the CFO of a cryptocurrency mining company and of an IT services organization. Mr. Ciullo is a CPA who obtained a Bachelor’s of Science in Accounting from SUNY Geneseo and an MBA from Pennsylvania State University
19
NITIN KAUSHAL, CPA
Chairman of the Board
Nitin Kaushal serves as Managing Director, Corporate Finance at PwC Canada. With over 30 years of finance and investment experience in the financial, healthcare and technology industries he has worked in senior roles with a number
- f
Canadian investment banks, including Desjardins Securities Inc., Orion Securities Inc., Vengate Capital Partners Company, HSBC Securities Inc., Medwell Capital Corp. and Gordon Capital, and has held various roles within the private equity/venture capital industry. In addition, he has sat on the boards of a number of public and private companies, including Patient Home Monitoring Corp., Convalo Health International, Delivra Inc., Global Gardens Group Inc., and Shelby Ventures.
JORDAN CROCKETT
Director
- Mr. Crockett currently owns and operates a progressive
commercial and residential construction company. He has been involved in the design and construction of cannabis cultivation facilities over the years. Mr. Crockett graduated with a degree in commerce specializing in finance at the University of British Columbia Sauder School of Business.
PATRICK GRAY
Director
- Mr. Gray is the founder and owner of sCube Inc. a niche IT
Service provider that focuses on E-Discovery, E-Licensing, Application Development and IOT and has been awarded Best Places to Work by the Business Review. Mr. Gray is also the Chief Executive Officer and founder of HashChain Technology Inc. (TSXV:KASH), a publicly traded cryptocurrency mining company. He currently serves on the board of Poda technologies Ltd. a zero-cleaning vaporizer system, harnessing innovative technology that can be paired with almost any vaporizable substance. The first start-up he was involved in was sold to Xerox for $220 million dollars and he stayed on to become the youngest executive in Xerox history.
CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019
APPENDIX
05
20
CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019
OUR PRODUCTS
21
Gummies
CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019
OUR PRODUCTS
21
Fluids
CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019
OUR PRODUCTS
22
Distillates
CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019
OUR PRODUCTS
23
Concentrates
CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019
SOME OF THE COMPANY’S PLANNED BUSINESS ACTIVITIES, WHILE BELIEVED TO BE COMPLIANT WITH APPLICABLE CERTAIN U.S. STATE AND LOCAL LAW, ARE ILLEGAL UNDER UNITED STATES FEDERAL LAW. Unlike in Canada which has federal legislation uniformly governing the cultivation, distribution, sale and possession of medical marijuana under the Access to Cannabis for Medical Purposes Regulations, it is cautioned that in the United States, marijuana is largely regulated at the state level. Although certain states and territories of the U.S. authorize medical or recreational cannabis production and distribution by licensed or registered entities, under U.S. federal law, the possession, use, cultivation, and transfer of cannabis and any related drug paraphernalia is illegal and any such acts are criminal acts under federal law under any and all circumstances under the U.S. Controlled Substances Act (“CSA”). Violations of any federal laws and regulations could result in significant fines, penalties, administrative sanctions, convictions or settlements arising from civil proceedings conducted by either the federal government or private citizens, or criminal charges, including but not limited to disgorgement of profits, cessation of business activities or divestiture. This could have a material adverse effect on the Company, including its reputation and ability to conduct business, its holding (directly or indirectly) of marijuana licenses in the United States, the listing of its securities on various stock exchanges, its financial position, operating results, profitability or liquidity or the market price of its publicly traded shares, if any. In addition, it is difficult to estimate the time or resources that would be needed for the investigation of any such matters or its final resolution because, in part, the time and resources that may be needed are dependent on the nature and extent of any information requested by the applicable authorities involved, and such time or resources could be substantial. In addition, since the possession and use of cannabis and any related drug paraphernalia is illegal under U.S. federal law, the Company may be deemed to be aiding and abetting illegal activities through the contracts it has entered into and the products that it intends to provide. As a result, U.S. law enforcement authorities, in their attempt to regulate the illegal use of cannabis and any related drug paraphernalia, may seek to bring an action or actions against the Company, including, but not limited to, aiding and abetting another’s criminal activities. The Federal aiding and abetting statute provides that anyone who “commits an offense against the United States or aids, abets, counsels, commands, induces or procures its commission, is punishable as a principal.” As a result of such an action, the Company may be forced to cease operations. Such an action would have a material negative effect on our business and operations. THE COMPANY’S INVESTMENTS AND OPERATIONS IN THE UNITED STATES MAY BE SUBJECT TO HEIGHTENED SCRUTINY. For the reasons set forth above, the Company’s existing investments and operations in the United States, and any future investments or operations, may become the subject of heightened scrutiny by regulators, stock exchanges and other authorities in Canada. As a result, the Company may be subject to significant direct and indirect interaction with public officials. There can be no assurance that this heightened scrutiny will not in turn lead to the imposition of certain restrictions on the Company’s ability to invest in the United States or any other jurisdiction. Relatedly, it has been reported by certain publications (the “Publications”) in Canada that The Canadian Depository for Securities Limited is considering a policy shift that would see its subsidiary, CDS Clearing and Depository Services Inc. ("CDS"), refuse to settle trades for cannabis issuers that have investments in the United States. CDS is Canada's central securities depository, clearing and settlement hub settling trades in the Canadian equity, fixed income and money markets. Although the TMX Group, the owner and operator of CDS, released a statement on August 17, 2017 confirming that there is no CDS ban on the clearing of securities of issuers with marijuana-related activities in the U.S., the TMX Group did indicate that it continues to work with regulators to arrive at a solution that will clarify this matter for issuers, investors, participants and the public. On February 8, 2018, CDS signed a memorandum of understanding (the “CDS MOU”) with the Aequitas NEO Exchange Inc., the CSE, the Toronto Stock Exchange and the TSX Venture Exchange (collectively, the “Exchanges”). The CDS MOU outlines CDS’ and the Exchanges’ understanding of Canada’s regulatory framework applicable to the rules and procedures and regulatory oversight of the Exchanges and CDS. The CDS MOU confirms, with respect to the clearing of listed securities, that CDS relies on the Exchanges to review the conduct of listed issuers. As a result, there is currently no CDS ban on the clearing of securities of issuers with cannabis-related activities in the U.S. However, if CDS were to proceed in the manner suggested by these publications, and apply such a policy to the Company, it would have a material adverse effect on the ability investors to make trades.. In particular, the Common Shares would be highly illiquid as investors would have no ability to effect a trade of the Common Shares through the facilities of a stock exchange in Canada. Government policy changes or public opinion may also result in a significant influence over the regulation of the cannabis industry in Canada, the United States
- r elsewhere. A negative shift in the public’s perception of medical or recreational
cannabis in the United States or any other applicable jurisdiction could affect future legislation or regulation. Among other things, such a shift could cause state jurisdictions to abandon initiatives or proposals to legalize medical and/or recreational cannabis, thereby limiting the number of new state jurisdictions into which the Company could expand. Any inability to fully implement the Company’s expansion strategy may have a material adverse effect on the Company’s business, financial condition and results of operations. REGULATORY SCRUTINY OF THE COMPANY’S INDUSTRY MAY NEGATIVELY IMPACT ITS ABILITY TO RAISE ADDITIONAL CAPITAL. The Company’s business activities rely on newly established and/or developing laws and regulations in various states in the United States. These laws and regulations are rapidly evolving and subject to change with minimal notice. Regulatory changes may adversely affect the Company’s profitability or cause it to cease operations entirely. The cannabis industry may come under the scrutiny or further scrutiny by the U.S. Food and Drug Administration, Securities and Exchange Commission, the DOJ, the Financial Industry Regulatory Advisory or other federal state or nongovernmental regulatory authorities or self-regulatory organizations that supervise or regulate the production, distribution, sale or use of cannabis for medical or nonmedical purposes in the United States. It is impossible to determine the extent of the impact of any new laws, regulations or initiatives that may be proposed, or whether any proposals will become law. The regulatory uncertainty surrounding the Company’s industry may adversely affect the business and operations of the Company, including without limitation, the costs to remain compliant with applicable laws and the impairment of its ability to raise additional capital, which could reduce, delay or eliminate any return on investment in the Company. THE SIZE OF THE COMPANY’S TARGET MARKET IS DIFFICULT TO QUANTIFY. Because the cannabis industry is in an early stage with uncertain boundaries, there is a lack of information about comparable companies and, few, if any, established companies whose business model the Company can follow or upon whose success the Company can build. Accordingly, there can be no assurance that the Company’s estimates are accurate or that the market size is sufficiently large for its business to grow as projected, which may negatively impact its financial results. The Company regularly purchases and follows market research.
RISK FACTORS
24
CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019
THE COMPANY MAY HAVE DIFFICULTY ACCESSING THE SERVICE OF BANKS AND PROCESSING CREDIT CARD PAYMENTS IN THE FUTURE, WHICH MAY MAKE IT DIFFICULT FOR THE COMPANY TO OPERATE. In February 2014, the Financial Crimes Enforcement Network (“FinCEN”) bureau of the U.S. Treasury Department issued guidance (which is not law) with respect to financial institutions providing banking services to cannabis business, including burdensome due diligence expectations and reporting requirements. This guidance does not provide any safe harbors or legal defenses from examination or regulatory
- r criminal enforcement actions by the DOJ, FinCEN or other federal regulators.
Thus, most banks and other financial institutions do not appear to be comfortable providing banking services to cannabis-related businesses, or relying on this guidance, which can be amended or revoked at any time by the Trump
- Administration. In addition to the foregoing, banks may refuse to process debit card
payments and credit card companies generally refuse to process credit card payments for cannabis-related businesses. As a result, the Company may have limited or no access to banking or other financial services in the United States, and may have to operate the Company’s U.S. business on an all-cash basis. The inability
- r limitation in the Company’s ability to open or maintain bank accounts, obtain
- ther banking services and/or accept credit card and debit card payments may
make it difficult for the Company to operate and conduct its business as planned. The Company is actively pursuing alternatives that ensure its operations will continue to be compliant with the FinCEN guidance and existing disclosures around cash management and reporting to the IRS once it moves from development into production. U.S. FEDERAL TRADEMARK AND PATENT PROTECTION MAY NOT BE AVAILABLE FOR THE INTELLECTUAL PROPERTY OF THE COMPANY DUE TO THE CURRENT CLASSIFICATION OF CANNABIS AS A SCHEDULE I CONTROLLED SUBSTANCE. As long as cannabis remains illegal under U.S. federal law as a Schedule I controlled substance pursuant to the CSA, the benefit of certain federal laws and protections which may be available to most businesses, such as federal trademark and patent protection regarding the intellectual property of a business, may not be available to the Company. As a result, the Company’s intellectual property may never be adequately or sufficiently protected against the use or misappropriation by third-
- parties. In addition, since the regulatory framework of the cannabis industry is in a
constant state of flux, the Company can provide no assurance that it will ever obtain any protection of its intellectual property, whether on a federal, state or local level. THE COMPANY’S CONTRACTS MAY NOT BE LEGALLY ENFORCEABLE IN THE UNITED STATES. Because the Company’s contracts involve cannabis and other activities that are not legal under U.S. federal law and in some jurisdictions, the Company may face difficulties in enforcing its contracts in U.S. federal and certain state courts. THERE IS UNCERTAINTY SURROUNDING THE TRUMP ADMINISTRATION AND ITS INFLUENCE AND POLICIES IN OPPOSITION TO THE CANNABIS INDUSTRY AS A WHOLE. The inconsistency between U.S. federal law and the laws of certain states concerning cannabis was addressed in August 2013 when then Deputy Attorney General, James Cole, authored the Cole Memorandum (the “Memorandum”). The Memorandum was addressed to all U.S. district attorneys acknowledging that notwithstanding the designation of cannabis as a controlled substance at the federal level in the U.S., several US states have enacted laws relating to cannabis for medical purposes. The Memorandum outlined certain priorities for the DOJ relating to the prosecution of cannabis offenses. In particular, the Memorandum noted that in jurisdictions that have enacted laws legalizing cannabis in some form and that have also implemented strong and effective regulatory and enforcement systems to control the cultivation, distribution, sale and possession of cannabis, conduct in compliance with those laws and regulations is less likely to be a priority at the federal level. Notably, however, the DOJ has never provided specific guidelines for what regulatory and enforcement systems it deems sufficient under the Memorandum standard. In light of limited investigative and prosecutorial resources, the Memorandum concluded that the DOJ should be focused on addressing only the most significant threats related to cannabis. States where medical cannabis had been legalized were not characterized as a high priority. On January 4, 2018, Former US Attorney General Jeff Sessions issued a memorandum to US district attorneys which rescinded the Memorandum. With the Memorandum rescinded, US federal prosecutors may exercise their discretion in determining whether to prosecute compliant state law cannabis-related operations as violations of U.S. federal law throughout the U.S. The practical impact of the decision to rescind the Memorandum is unknown and may have a material adverse effect on the Corporation’s business and results of operations. DUE TO THE CLASSIFICATION OF CANNABIS AS A SCHEDULE I CONTROLLED SUBSTANCE UNDER THE CSA, BANKS AND OTHER FINANCIAL INSTITUTIONS WHICH SERVICE THE CANNABIS INDUSTRY ARE AT RISK OF VIOLATING CERTAIN FINANCIAL LAWS, INCLUDING ANTI-MONEY LAUNDERING STATUTES. Because the manufacture, distribution, and dispensation of cannabis remains illegal under the CSA, banks and other financial institutions providing services to cannabis- related businesses risk violation of federal anti-money laundering statutes (18 U.S.C. §§ 1956 and 1957), the unlicensed money-remitter statute (18 U.S.C. § 1960) and the U.S. Bank Secrecy Act. These statutes can impose criminal liability for engaging in certain financial and monetary transactions with the proceeds of a “specified unlawful activity” such as distributing controlled substances which are illegal under federal law, including cannabis, and for failing to identify or report financial transactions that involve the proceeds of cannabis-related violations of the CSA. The Company may also be exposed to the foregoing risks. In the event that any of the Company’s investments, or any proceeds thereof, any dividends or distributions therefrom, or any profits or revenues accruing from such investments in the United States were found to be in violation of money laundering legislation or otherwise, such transactions may be viewed as proceeds of crime under one or more of the statutes noted above or any other applicable legislation. This could restrict or
- therwise jeopardize the ability of the Company to declare or pay dividends, effect
- ther distributions or subsequently repatriate such funds back to Canada in the
foreseeable future, in the event that a determination was made that any such investments in the United States could reasonably be shown to constitute proceeds
- f crime, the Company may decide or be required to suspend declaring or paying
dividends without advance notice and for an indefinite period of time. Securities legislation in certain provinces and territories of Canada provides purchasers of securities with, in addition to any other right they may have at law, rights of rescission or damages, or both, where any document, purporting to describe the business and affairs of an issuer that has been prepared primarily for delivery to and review by a prospective purchaser so as to assist the prospective purchaser to make an investment decision in respect of securities and, in some cases, advertising and sales literature used in connection with the offering of the
- ffered securities, contains a misrepresentation. For the purposes of this section,
“misrepresentation” means: (a) an untrue statement of a fact that significantly affects, or would reasonably be expected to have a significant effect, on the market price or the securities of the Company (a “material fact”); or (b) an omission to state a material fact that is required to be stated or that is necessary to make a statement not misleading in the light of the circumstances in which it was made. These rights must be exercised by purchasers of the offered securities within the prescribed time limits under applicable securities legislation. Purchasers should refer to the applicable provisions of the securities legislation of their province or territory for the full particulars of these rights or consult with their legal advisor.
25
RISK FACTORS
CANNAMERICA BRANDS CORPORATE PRESENTATION | 2019
THANK YOU
CONTACT
INVESTOR RELATIONS info@cannamericabrands.com
- t. 1.844.484.3996
26
CSE:CANA OTC:CNNXF